Sur cette page
01PTCT prix
02Aperçu
03Graphique
05À propos
06Performance
07Valorisation et ratios
14Bénéfices
15Fondamentaux complets
16États financiers
17Détenteurs institutionnels (13F)
18Activistes et détenteurs de 5%+
19Initiés de la société
20Détention d'ETF
21Consensus
22Pairs
25Signaux de trading
26Mes métriques
PTCT PTC Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Voir sur SEC EDGAR ↗ clôture Oct 2, 2026 10-K/10-Q Jul 30, 2026
$63,46
· % de la fourchette 52 sem.
· au-dessus du plus bas
· vers le haut
$61,23Bas 52 semaines
$90,87Haut 52 semaines
Capitalisation Boursière (MRQ)
$5.29B
P/E (TTM)
-117.5
BPA (TTM)
$-0.54
Revenu (TTM)
$1.01B
vos badges
Fourchette 52 semaines
$61–$91
Note des analystes
BUY
Objectif de cours
$102
P/E
-117.5
ROE
20.6%
Marge nette
-3.8%
Votre barre de badges est vide — épinglez une métrique n'importe où sur cette page.
PTCT Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
Prix
$63.46
Capitalisation Boursière (MRQ)
$5.29B
P/E (TTM)
-117.5
BPA (TTM)
$-0.54
Revenu (TTM)
$1.01B
ROE (TTM)
20.6%
Dette/Capitaux propres (MRQ)
-3.6
Fourchette 52 semaines
$61–$91
PTCT Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
fourchette
barres
La granularité des barres s'adapte à la période sélectionnée — survolez le graphique pour voir l'ouverture/le maximum/le minimum/la clôture d'une barre.
À propos de PTC Therapeutics, Inc. - Common Stock Présentation de l'entreprise depuis Wikipedia
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.
Products
In 2017, PTC acquired Emflaza (deflazacort) from Marathon Pharmaceuticals. PTC also owns Translarna, (Ataluren) marketed for nonsense mutation Duchenne muscular dystrophy. Together, the two products generated revenues of 174 million dollars and 260 million dollars in 2017 and 2018 respectively.
PTC has the commercialization rights for WAYLIVRA (volanesorsen) in Latin America.
In 2018, PTC acquired Agilis Biotherapeutics and a gene therapy candidate, GT-AADC, with its compelling clinical data in treating aromatic L-amino acid decarboxylase (AADC) deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase (DDC) gene. As of 2024, the AAV based treatment for AADC deficiency has been approved by the FDA and commercialized in the United States as Kebilidi. It is the first FDA-approved gene therapy treatment for AADC deficiency. This same product was granted EMA approval for use in the European Union under the name Upstaza.
Pipeline
In 2020, PTC acquired Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth.
In 2020, PTC announced the FDA approval of Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older.
In 2024, Novartis has committed $1 billion upfront in a licensing deal with PTC Therapeutics for an experimental treatment for Huntington’s disease, with the potential for an additional $1.9 billion tied to achieving specific development, regulatory, and commercial milestones. PTC Therapeutics’ therapy, known as PTC518, is an oral medication designed to reduce the production of the mutant protein linked to the genetic mutation responsible for the disease. This mutant protein is believed to contribute to neuronal death, driving disease progression. In June, interim data from a Phase 2 trial indicated that PTC518 successfully lowered levels of the mutant protein in both blood and cerebrospinal fluid.
Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗
secteurHealthcare
industrieBiotechnology
employés991
paysUS
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Revenu$1.73B2016-12-31 → 2025-12-31
BPA$7.782019-12-31 → 2025-12-31
Flux de trésorerie libre$702M2016-12-31 → 2025-12-31
Marge nette-3.8%2016-12-31 → 2025-12-31
Valorisation et Ratios
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
| Métrique | Tendance sur 5 ans | PTCT | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -117.5moyenne 5 ans ≈-2.7 | ≈-2.7 | · | · | |
| P/S (TTM) | 5.2moyenne 5 ans ≈3.8 | ≈3.8 | 55.0 | Sous-évalué | |
| P/B (MRQ) | -32.0moyenne 5 ans ≈481.5 | ≈481.5 | · | · | |
| EV / EBITDA (TTM) | 20.2moyenne 5 ans ≈-5.5 | ≈-5.5 | · | · | |
| Cours / FCF (TTM) | -133.2moyenne 5 ans ≈-10.8 | ≈-10.8 | · | · | |
| Cours / Flux de trésorerie (TTM) | -173.4moyenne 5 ans ≈-12.1 | ≈-12.1 | · | · | |
| VE / Chiffre d'affaires (TTM) | 3.6moyenne 5 ans ≈3.0 | ≈3.0 | · | · | |
| VE / FCF (TTM) | -91.9moyenne 5 ans ≈-8.4 | ≈-8.4 | · | · | |
| Cours / Actif net tangible (MRQ) | -9.3 | · | · | · |
La médiane des pairs est calculée sur une base standardisée par métrique et peut ne pas toujours correspondre à la base TTM/MRQ indiquée pour cette action.
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
| Métrique | Tendance sur 5 ans | PTCT | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Marge d'exploitation (TTM) | 12.5%moyenne 5 ans ≈-25.9% | ≈-25.9% | -24.1% | Premier rang | |
| Marge EBITDA (TTM) | 17.9%moyenne 5 ans ≈-13.8% | ≈-13.8% | -24.1% | Premier rang | |
| Marge avant impôts (TTM) | -6.6%moyenne 5 ans ≈-43.8% | ≈-43.8% | -28.9% | Premier rang | |
| Marge nette (TTM) | -3.8%moyenne 5 ans ≈-42.4% | ≈-42.4% | -38.1% | Premier rang | |
| ROA (TTM) | -1.3%moyenne 5 ans ≈-12.6% | ≈-12.6% | -27.7% | Premier rang | |
| ROE (TTM) | 20.6%moyenne 5 ans ≈-299.7% | ≈-299.7% | -40.8% | Faible | |
| ROIC | 1044.7%moyenne 5 ans ≈267.1% | ≈267.1% | -37.7% | Premier rang |
Santé financière Dette, liquidité, solvabilité — solidité du bilan
| Métrique | Tendance sur 5 ans | PTCT | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Dette / Capitaux propres (MRQ) | -3.6moyenne 5 ans ≈74.5 | ≈74.5 | · | · | |
| Ratio de liquidité (MRQ) | 3.4moyenne 5 ans ≈2.1 | ≈2.1 | 8.3 | Faible liquidité | |
| Ratio de liquidité réduite (MRQ) | 3.2moyenne 5 ans ≈2.0 | ≈2.0 | 3.2 | En ligne | |
| Dette à long terme / Capitaux propres (MRQ) | -3.2moyenne 5 ans ≈65.1 | ≈65.1 | · | · |
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
| Métrique | Tendance sur 5 ans | PTCT | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Revenue YoY (Chiffre d'affaires YoY) | 114.5%moyenne 5 ans ≈41.2% | ≈41.2% | · | · | |
| Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans) | 35.3%moyenne 5 ans ≈28.3% | ≈28.3% | · | · | |
| Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans) | 35.4% | · | · | · |
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
| Métrique | Tendance sur 5 ans | PTCT | moyenne 5 ans | Médiane des pairs | Verdict |
|---|---|---|---|---|---|
| Asset Turnover (Rotation des actifs) | 0.8moyenne 5 ans ≈0.5 | ≈0.5 | 0.4 | Premier rang | |
| Receivables Turnover (Rotation des créances) | 10.2moyenne 5 ans ≈6.8 | ≈6.8 | 9.7 | En ligne | |
| Revenue / Employee (Chiffre d'affaires annuel ÷ employés (effectif déclaré, yfinance). Dérivé — pas un concept SEC-XBRL stocké.) | ≈$1.7M | · | · | · |
valeur · ≈ moyenne 5 ans · médiane du secteur · verdict par rapport à la médiane
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
Surprise Moyenne
105.2%
Prochain rapport
Nov 02, 2026
| Période | Rapport | EPS Actual | BPA est. | Surprise |
|---|---|---|---|---|
| 30 juin 2026 | Aoû 5, 2026 | $0.92 | $0.43 | 116.4% |
| 31 mars 2026 | $-0.03 | $-0.48 | 93.7% | |
| 31 décembre 2025 | $-1.67 | $0.04 | -4460.3% | |
| 30 septembre 2025 | $0.20 | $-1.40 | 114.3% | |
| 30 juin 2025 | $-0.83 | $-1.08 | 23.3% | |
| 31 mars 2025 | $10.04 | $-0.22 | 4743.8% |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Cost of Revenue | · | · | · | · | · | · | $12M | $13M | $5M | $0 | $0 | · | |
| R&D Expense | $455M | $534M | $667M | $651M | $541M | $478M | $257M | $172M | $117M | $118M | $122M | $80M | |
| SG&A Expense | $347M | $301M | $333M | $326M | $286M | $245M | $203M | $154M | $121M | $97M | $82M | $45M | |
| Operating Expenses | $864M | $1.11B | $1.38B | $1.15B | $913M | $813M | $548M | $380M | $259M | $215M | $204M | $125M | |
| Operating Income | $867M | $-303M | $-440M | $-447M | $-374M | $-432M | $-241M | $-116M | $-64M | $-132M | $-167M | $-99M | |
| Other Non-op | $-18M | $7M | $10M | $-49M | $-58M | $85M | $14M | $129.0K | $-1M | $-1M | $-465.0K | $-213.0K | |
| Pretax Income | $697M | $-363M | $-696M | $-587M | $-518M | $-403M | $-240M | $-128M | $-78M | $-142M | $-170M | $-98M | |
| Income Tax | $14M | $176.0K | $-70M | $-28M | $6M | $35M | $12M | $-29.0K | $1M | $569.0K | $485.0K | $-5M | |
| Net Income | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| EPS (Basic) | $8.58 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-2.75 | $-2.02 | · | · | $-2.97 | |
| EPS (Diluted) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | · | · | · | · | $-2.97 | |
| Shares (Basic) | 79,534,290 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| Shares (Diluted) | 88,311,494 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| EBITDA | $906M | $-227M | $-203M | · | $-310M | $-388M | $-209M | $-90M | $-47M | $-132M | $-167M | $-99M |
Bilan
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $985M | $780M | $594M | $280M | $190M | $209M | $288M | $169M | $112M | $58M | $58M | $50M | |
| Short-term Investments | $961M | $360M | $283M | $131M | $584M | $895M | $399M | $58M | $79M | $173M | $281M | $265M | |
| Receivables | $182M | $159M | $161M | $156M | $110M | $70M | $56M | $68M | $40M | $25M | $11M | $4M | |
| Inventory | $80M | $23M | $31M | $22M | $16M | $19M | $19M | $16M | $11M | $0 | · | · | |
| Prepaid Expense | $67M | $44M | $150M | $106M | $55M | $39M | $18M | $9M | $7M | $5M | $6M | $4M | |
| Current Assets | $2.27B | $1.37B | $1.22B | $694M | $954M | $1.23B | $779M | $321M | $249M | $261M | $356M | $324M | |
| PP&E (Net) | $55M | $61M | $87M | $73M | $53M | $34M | $22M | $13M | $8M | $7M | $9M | $9M | |
| PP&E (Gross) | $102M | $94M | $138M | $110M | $80M | $52M | $33M | $20M | $41M | $38M | $37M | $34M | |
| Accum. Depreciation | $47M | $33M | $51M | $37M | $27M | $18M | $12M | $7M | $33M | $31M | $28M | $25M | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $0 | · | · | · | |
| Intangibles | $389M | $119M | $379M | $706M | $725M | $715M | $710M | $701M | $133M | $0 | · | · | |
| Total Assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Accounts Payable | $45M | $17M | $6M | $27M | $23M | $19M | $10M | $6M | $15M | $6M | $6M | $4M | |
| Current Liabilities | $968M | $581M | $603M | $406M | $509M | $277M | $236M | $167M | $82M | $50M | $45M | $32M | |
| Capital Leases | $94M | $75M | $98M | $101M | $74M | $79M | $9M | · | · | · | · | · | |
| Deferred Tax | · | · | $56M | $103M | $137M | $137M | $131M | $122M | $0 | · | · | · | |
| Other Non-current Liabilities | $14M | $21M | $141.0K | $3M | · | $1M | $141.0K | $58.0K | $243.0K | $335.0K | $2M | $2M | |
| Total Liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B | $1.73B | $1.03B | $768M | $235M | $150M | $139M | $35M | |
| Long-term Debt | · | · | · | · | $431M | · | $314M | $153M | $145M | · | · | · | |
| Total Debt | $287M | $285M | $284M | · | $431M | $309M | $314M | $153M | $145M | $98M | $95M | · | |
| Common Stock | $80.0K | $77.0K | $75.0K | $72.0K | $71.0K | $70.0K | $62.0K | $51.0K | $42.0K | $34.0K | $34.0K | $33.0K | |
| Paid-in Capital | $2.75B | $2.57B | $2.47B | $2.31B | $2.12B | $2.17B | $1.80B | $1.29B | $967M | $856M | $820M | $722M | |
| Retained Earnings | $-2.96B | $-3.65B | $-3.28B | $-2.66B | $-2.10B | $-1.63B | $-1.19B | $-939M | $-814M | $-735M | $-593M | $-423M | |
| AOCI | $11M | $-26M | $-1M | $5M | $-24M | $-61M | $-11M | $1M | $4M | $-1M | $-1M | $-737.0K | |
| Stockholders' Equity | $-205M | $-1.10B | $-819M | $-347M | $1M | $482M | $594M | $351M | $156M | $120M | $226M | $298M | |
| Liabilities + Equity | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Shares Outstanding | 81,474,366 | 77,704,188 | 75,708,889 | 73,104,692 | 70,828,226 | 69,718,096 | 61,935,870 | 50,606,147 | 41,612,395 | 34,169,410 | 33,916,559 | 32,898,392 |
Flux de trésorerie
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $39M | $76M | $237M | $129M | $64M | $43M | $32M | $26M | $18M | $3M | $3M | · | |
| Stock-based Comp | $75M | $75M | $102M | $110M | $104M | $70M | $42M | $33M | $31M | $35M | $34M | $19M | |
| Deferred Tax | $-3.0K | $-56M | $-47M | $-34M | $377.0K | $6M | $9M | $0 | $199.0K | $-199.0K | $0 | $0 | |
| Amort. of Intangibles | $25M | $61M | $223M | $117M | $55M | $37M | $28M | $23M | $15M | $0 | $0 | · | |
| Restructuring | · | · | · | · | · | · | · | · | $0 | · | · | · | |
| Other Non-cash | $-85M | $161M | $177M | · | $105M | $124M | $70M | $41M | $20M | · | · | · | |
| Operating Cash Flow | $711M | $-108M | $-158M | $-357M | $-251M | $-194M | $-99M | $-28M | $-10M | $-104M | $-124M | $-57M | |
| CapEx | $9M | $7M | $28M | $32M | $28M | $18M | $14M | $7M | $3M | $2M | $3M | $5M | |
| Investing Cash Flow | $-862M | $44M | $-177M | $290M | $219M | $-562M | $-387M | $-43M | $13M | $104M | $-21M | $-145M | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | $0 | · | $-49.0K | |
| Stock Issued | · | · | · | · | · | $28M | $324M | $118M | $0 | $0 | $0 | $236M | |
| Net Stock Activity | · | · | · | · | · | $28M | $324M | $118M | · | $0 | · | $236M | |
| Financing Cash Flow | $331M | $256M | $646M | $168M | $21M | $669M | $613M | $132M | $44M | $968.0K | $154M | $237M | |
| Net Change in Cash | $203M | $185M | $314M | $99M | $-19M | $-79M | $126M | $58M | $53M | $299.0K | $8M | $34M | |
| Taxes Paid | $37M | $18M | $14M | $5M | $8M | $26M | $2M | $2M | $1M | $943.0K | $111.0K | $0 | |
| Free Cash Flow | $702M | $-114M | $-187M | · | $-280M | $-212M | $-112M | $-35M | $-13M | $-105M | $-127M | $-62M |
Rentabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 50.1% | -37.5% | -46.9% | · | -69.5% | -113.4% | -78.6% | -43.7% | -33.1% | -159.7% | -454.6% | -393.8% | |
| Net Margin | 39.4% | -45.0% | -66.8% | · | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% | -463.6% | -371.4% | |
| Pretax Margin | 40.2% | -45.0% | -74.2% | · | -96.2% | -105.8% | -78.2% | -48.4% | -40.0% | -171.1% | -462.3% | -390.0% | |
| EBITDA Margin | 52.3% | -28.1% | -21.6% | · | -57.6% | -102.0% | -68.1% | -33.8% | -24.0% | -159.7% | -454.6% | -393.8% | |
| ROA | 29.7% | -20.2% | -34.8% | · | -25.3% | -22.9% | -18.3% | -17.0% | -23.9% | -44.8% | -48.6% | -38.6% | |
| ROE | -331.5% | 33.8% | 84.1% | · | -985.1% | -88.3% | -40.0% | -34.8% | -57.2% | -82.2% | -65.0% | -43.1% | |
| ROIC | 1044.7% | 37.2% | 74.0% | · | -87.4% | -59.4% | -27.8% | -23.0% | -21.7% | -60.9% | -52.3% | -31.7% |
Liquidité et Solvabilité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 2.4 | 2.0 | · | 1.9 | 4.4 | 3.3 | 1.9 | 3.0 | 5.3 | 7.8 | 10.0 | |
| Quick Ratio | 2.2 | 2.2 | 1.7 | · | 1.7 | 4.2 | 3.1 | 1.8 | 2.8 | 5.2 | 7.7 | 9.8 | |
| Debt / Equity | -1.4 | -0.3 | -0.3 | · | 300.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · | |
| LT Debt / Equity | · | -0.3 | -0.3 | · | 196.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · |
Efficacité
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.4 | 0.5 | · | 0.3 | 0.2 | 0.2 | 0.4 | 0.6 | 0.3 | 0.1 | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | 0.7 | · | 0.9 | · | · | · | |
| Receivables Turnover | 10.2 | 5.1 | 5.9 | · | 6.0 | 6.1 | 5.0 | 4.9 | 6.0 | 4.6 | 4.7 | 9.3 |
Par action
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-2.52 | $-14.13 | $-10.81 | · | $0.02 | $6.91 | $9.60 | $6.93 | $3.76 | $3.50 | $6.66 | $9.07 | |
| Revenue / Share | $19.60 | $10.50 | $12.53 | · | $7.64 | · | · | · | · | · | · | $0.80 | |
| Cash Flow / Share | $8.05 | $-1.40 | $-2.12 | · | $-3.57 | · | · | · | · | · | · | $-1.81 | |
| Cash / Share | $12.09 | $10.03 | $7.85 | · | $2.68 | $3.00 | $4.65 | $3.35 | $2.69 | $1.71 | $1.71 | $1.51 | |
| EPS (TTM) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-3.21 | $-3.21 | $-3.21 | $-3.21 | $-2.97 |
Taux de croissance
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 114.5% | -14.0% | 34.2% | 29.8% | 41.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 35.3% | 14.4% | 35.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 35.4% | · | · | · | · | · | · | · | · | · | · | · |
Valorisation (TTM)
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Net Income TTM | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| Market Cap | $6.19B | $3.51B | $2.09B | · | $2.82B | $4.25B | $2.97B | $1.74B | $694M | $373M | $1.10B | $1.70B | |
| Enterprise Value | $4.53B | $2.65B | $1.49B | · | $2.48B | $3.46B | $2.60B | $1.66B | $648M | $239M | $855M | · | |
| P/E | 9.8 | -9.5 | -3.3 | -4.9 | -5.4 | -9.2 | -11.2 | -10.7 | -5.2 | -3.4 | -10.1 | -17.4 | |
| P/S | 3.6 | 4.3 | 2.2 | · | 5.2 | 11.2 | 9.7 | 6.6 | 3.6 | 4.5 | 29.9 | 67.5 | |
| P/B | -30.1 | -3.2 | -2.5 | · | 1961.8 | 8.8 | 5.0 | 5.0 | 4.4 | 3.1 | 4.9 | 5.7 | |
| P / Cash Flow | 8.7 | -32.6 | -13.2 | · | -11.2 | -21.9 | -30.2 | -62.8 | -69.0 | -3.6 | -8.8 | -29.7 | |
| P / FCF | 8.8 | -30.7 | -11.2 | · | -10.1 | -20.1 | -26.5 | -50.0 | -52.7 | -3.5 | -8.6 | -27.5 | |
| EV / EBITDA | 5.0 | -11.7 | -7.4 | · | -8.0 | -8.9 | -12.5 | -18.6 | -13.9 | -1.8 | -5.1 | · | |
| EV / FCF | 6.5 | -23.2 | -8.0 | · | -8.9 | -16.3 | -23.2 | -47.9 | -49.2 | -2.3 | -6.7 | · | |
| EV / Revenue | 2.6 | 3.3 | 1.6 | · | 4.6 | 9.1 | 8.5 | 6.3 | 3.3 | 2.9 | 23.2 | · | |
| Earnings Yield | 10.2% | -10.5% | -30.4% | -20.4% | -18.6% | -10.9% | -8.9% | -9.3% | -19.2% | -29.4% | -9.9% | -5.7% |
Compte de résultat
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $361M | $273M | $165M | $211M | $179M | $1.18B | $213M | $197M | $187M | $210M | $307M | $197M | $214M | $220M | $167M | $217M | |
| R&D Expense | $99M | $101M | $133M | $100M | $113M | $109M | $125M | $161M | $132M | $116M | $121M | $164M | $186M | $195M | $189M | $165M | |
| SG&A Expense | $81M | $86M | $97M | $84M | $85M | $81M | $85M | $73M | $70M | $73M | $76M | $81M | $88M | $87M | $93M | $80M | |
| Operating Expenses | $212M | $228M | $236M | $208M | $214M | $206M | $376M | $251M | $227M | $256M | $301M | $315M | $423M | $338M | $368M | $285M | |
| Operating Income | $149M | $45M | $-71M | $3M | $-35M | $970M | $-162M | $-55M | $-40M | $-45M | $6M | $-118M | $-210M | $-118M | $-200M | $-68M | |
| Other Non-op | $-3M | $2M | $-13M | $7M | $-6M | $-6M | $9M | $-2M | $-2M | $2M | $19M | $-20M | $1M | $10M | $35M | $-38M | |
| Pretax Income | $98M | $-2M | $-139M | $-23M | $-71M | $930M | $-95M | $-98M | $-86M | $-85M | $-157M | $-167M | $-237M | $-135M | $-190M | $-127M | |
| Income Tax | $14M | $347.0K | $-4M | $-39M | $-6M | $63M | $-29M | $9M | $13M | $7M | $-1M | $-34M | $-39M | $4M | $-19M | $-18M | |
| Net Income | $83M | $-3M | $-135M | $16M | $-65M | $867M | $-66M | $-107M | $-99M | $-92M | $-156M | $-133M | $-199M | $-139M | $-171M | $-109M | |
| EPS (Basic) | $1.01 | $-0.03 | $-1.88 | $0.20 | $-0.83 | $11.09 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| EPS (Diluted) | $0.92 | $-0.03 | $-1.63 | $0.20 | $-0.83 | $10.04 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| Shares (Basic) | 83,006,808 | 82,521,023 | · | 78,471,119 | 78,151,240 | 78,115,836 | · | 76,925,523 | 76,725,070 | 76,496,127 | · | 75,377,997 | 74,730,433 | 73,729,284 | · | 71,654,671 | |
| Shares (Diluted) | 92,020,009 | 82,521,023 | · | 87,115,369 | 78,151,240 | 86,385,922 | · | 76,925,523 | 76,725,070 | 76,496,127 | · | 75,377,997 | 74,730,433 | 73,729,284 | · | 71,654,671 | |
| EBITDA | $149M | $60M | · | $3M | $-35M | $977M | · | $-55M | $-40M | $10M | · | $-118M | $-210M | $-75M | · | $-68M |
Bilan
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.05B | $834M | $985M | $673M | $1.02B | $1.48B | $780M | $526M | $655M | $548M | · | $165M | $208M | $167M | · | $104M | |
| Short-term Investments | $1.18B | $1.06B | $961M | $1.02B | $972M | $547M | $360M | $487M | $439M | $336M | · | $130M | $130M | $119M | · | $184M | |
| Receivables | $239M | $220M | $182M | $203M | $196M | $210M | $159M | $200M | $187M | $198M | · | $166M | $178M | $202M | · | $124M | |
| Inventory | $91M | $76M | $80M | $53M | $34M | $22M | $23M | $36M | $32M | $30M | · | $36M | $32M | $27M | · | $15M | |
| Prepaid Expense | $58M | $66M | $67M | $64M | $54M | $57M | $44M | $33M | $46M | $56M | · | $44M | $42M | $99M | · | $90M | |
| Current Assets | $2.62B | $2.25B | $2.27B | $2.01B | $2.27B | $2.32B | $1.37B | $1.28B | $1.36B | $1.17B | · | $540M | $590M | $613M | · | $517M | |
| PP&E (Net) | $51M | $53M | $55M | $57M | $57M | $59M | $61M | $63M | $66M | $93M | · | $85M | $82M | $79M | · | $67M | |
| PP&E (Gross) | · | · | $102M | · | · | · | $94M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $33M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | · | $82M | $82M | $82M | · | $82M | |
| Intangibles | $403M | $381M | $389M | $396M | $144M | $118M | $119M | $330M | $330M | $330M | · | $423M | $452M | $686M | · | $750M | |
| Total Assets | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Accounts Payable | $40M | $25M | $45M | $37M | $27M | $15M | $17M | $13M | $24M | $27M | · | $19M | $26M | $26M | · | $21M | |
| Current Liabilities | $771M | $924M | $968M | $866M | $628M | $595M | $581M | $611M | $610M | $575M | · | $492M | $476M | $442M | · | $420M | |
| Capital Leases | $88M | $90M | $94M | $95M | $71M | $74M | $75M | $83M | $79M | $105M | · | $100M | $100M | $100M | · | $102M | |
| Deferred Tax | · | · | · | · | · | · | · | $56M | $56M | $56M | · | $52M | $52M | $103M | · | $137M | |
| Other Non-current Liabilities | $15M | $14M | $14M | $3M | $8M | $22M | $21M | $77.0K | $141.0K | $141.0K | · | $141.0K | $141.0K | $141.0K | · | $5M | |
| Total Liabilities | $3.42B | $3.05B | $3.10B | $2.80B | $2.84B | $2.84B | $2.80B | $2.90B | $2.90B | $2.68B | · | $1.93B | $1.92B | $2.07B | · | $1.80B | |
| Long-term Debt | $591M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $591M | $287M | · | $286M | $286M | $286M | · | $285M | $285M | $285M | · | $573M | $573M | $572M | · | $283M | |
| Common Stock | $82.0K | $81.0K | $80.0K | $79.0K | $78.0K | $78.0K | $77.0K | $76.0K | $76.0K | $76.0K | · | $75.0K | $75.0K | $73.0K | · | $71.0K | |
| Paid-in Capital | $2.71B | $2.78B | $2.75B | $2.67B | $2.63B | $2.61B | $2.57B | $2.53B | $2.51B | $2.49B | · | $2.45B | $2.42B | $2.34B | · | $2.22B | |
| Retained Earnings | $-2.88B | $-2.97B | $-2.96B | $-2.83B | $-2.85B | $-2.78B | $-3.65B | $-3.58B | $-3.47B | $-3.38B | · | $-3.13B | $-2.99B | $-2.80B | · | $-2.49B | |
| AOCI | $6M | $8M | $11M | $6M | $7M | $-14M | $-26M | $-4M | $-16M | $-6M | · | $10M | $-1M | $-2M | · | $36M | |
| Stockholders' Equity | $-165M | $-180M | $-205M | $-156M | $-207M | $-186M | $-1.10B | $-1.05B | $-980M | $-894M | $-819M | $-671M | $-579M | $-458M | $-347M | $-227M | |
| Liabilities + Equity | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Shares Outstanding | 83,327,286 | 82,882,024 | 81,474,366 | 79,931,766 | 79,378,145 | 79,225,276 | 77,704,188 | 76,952,124 | 76,900,123 | 76,653,960 | · | 75,459,022 | 75,318,233 | 74,012,034 | · | 71,854,892 |
Flux de trésorerie
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $16M | $15M | $13M | $11M | $8M | $7M | $7M | $6M | $7M | $55M | $81M | $62M | $51M | $43M | $39M | $34M | |
| Stock-based Comp | $23M | $23M | $19M | $19M | $19M | $18M | $17M | $20M | $19M | $18M | $17M | $27M | $29M | $29M | $27M | $29M | |
| Deferred Tax | · | $-10.0K | $1.0K | · | · | $2.0K | $-56M | $-3.0K | $2.0K | $-1.0K | $4M | $-2.0K | $-51M | $-4.0K | · | · | |
| Amort. of Intangibles | $12M | $12M | $9M | $8M | $4M | $4M | $3M | $3M | $3M | $52M | $77M | $59M | $47M | $39M | $36M | $31M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $23M | $8M | · | · | · | |
| Other Non-cash | · | $-95M | · | · | · | $-22M | · | · | · | $89M | · | · | · | $38M | · | · | |
| Operating Cash Flow | $129M | $-59M | $-34M | $-66M | $-58M | $870M | $-30M | $-77M | $-71M | $71M | $-100M | $-15M | $-14M | $-29M | $-166M | $-38M | |
| CapEx | $2M | $1M | $2M | $3M | $1M | $2M | $4M | $522.0K | $-7M | $10M | $6M | $6M | $6M | $10M | $9M | $5M | |
| Investing Cash Flow | $-123M | $-94M | $34M | $-290M | $-422M | $-184M | $268M | $-43M | $-66M | $-115M | $-94M | $-30M | $-24M | $-29M | $32M | $136M | |
| Financing Cash Flow | $212M | $6M | $303M | $15M | $4M | $9M | $26M | $-18M | $246M | $540.0K | $620M | $3M | $18M | $4M | $303M | $-140M | |
| Net Change in Cash | $216M | $-148M | $312M | $-347M | $-463M | $701M | $256M | $-129M | $104M | $-46M | $429M | $-43M | $-9M | $-62M | $175M | $-54M | |
| Taxes Paid | · | · | $-3M | $936.0K | $36M | $3M | $5M | $7M | $4M | $2M | $524.0K | $4M | $7M | $2M | $893.0K | $1M | |
| Free Cash Flow | · | $-60M | · | · | · | $868M | · | · | · | $61M | · | · | · | $-40M | · | · |
Rentabilité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 41.3% | 16.5% | · | 1.4% | -19.5% | 82.5% | · | -27.7% | -21.5% | -21.6% | · | -60.1% | -98.0% | -53.4% | · | -31.4% | |
| Net Margin | 23.2% | -1.0% | · | 7.5% | -36.2% | 73.7% | · | -54.2% | -53.1% | -43.6% | · | -67.6% | -93.0% | -63.0% | · | -50.3% | |
| Pretax Margin | 27.1% | -0.90% | · | -10.9% | -39.7% | 79.1% | · | -49.8% | -45.9% | -40.3% | · | -84.8% | -111.1% | -61.3% | · | -58.6% | |
| EBITDA Margin | 41.3% | 22.1% | · | 1.4% | -19.5% | 83.1% | · | -27.7% | -21.5% | 4.7% | · | -60.1% | -98.0% | -33.9% | · | -31.4% | |
| ROA | 2.8% | -0.10% | · | 0.71% | -2.9% | 39.0% | · | -6.9% | -6.1% | -5.4% | · | -9.4% | -12.7% | -8.2% | · | -6.1% | |
| ROE | -44.9% | 1.5% | · | -2.6% | 10.9% | -160.5% | · | 12.4% | 12.7% | 13.6% | · | 29.6% | 52.2% | 50.7% | · | 179.2% | |
| ROIC | 30.0% | 48.2% | · | -1.6% | -40.2% | 904.6% | · | 7.7% | 6.7% | 8.1% | · | 96.6% | 2648.9% | -105.7% | · | -104.9% |
Liquidité et Solvabilité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 2.4 | · | 2.3 | 3.6 | 3.9 | · | 2.1 | 2.2 | 2.0 | · | 1.1 | 1.2 | 1.4 | · | 1.2 | |
| Quick Ratio | 3.2 | 2.3 | · | 2.2 | 3.5 | 3.8 | · | 2.0 | 2.1 | 1.9 | · | 0.9 | 1.1 | 1.1 | · | 1.0 | |
| Debt / Equity | -3.6 | -1.6 | · | -1.8 | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 | |
| LT Debt / Equity | -3.2 | · | · | · | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 |
Efficacité
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.5 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.7 | 1.3 | · | 1.0 | 0.9 | 5.8 | · | 1.1 | 1.0 | 1.1 | · | 1.4 | 1.4 | 1.3 | · | 2.0 |
Par action
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-1.98 | $-2.18 | · | $-1.95 | $-2.60 | $-2.34 | · | $-13.70 | $-12.75 | $-11.66 | · | $-8.89 | $-7.69 | $-6.18 | · | $-3.16 | |
| Revenue / Share | $3.92 | $3.30 | · | $2.42 | $2.29 | $13.61 | · | $2.56 | $2.43 | $2.75 | · | $2.61 | $2.86 | $2.99 | · | $3.03 | |
| Cash Flow / Share | · | $-0.72 | · | · | · | $10.07 | · | · | · | $0.93 | · | · | · | $-0.40 | · | · | |
| Cash / Share | $12.60 | $10.06 | · | $8.41 | $12.82 | $18.68 | · | $6.84 | $8.51 | $7.15 | · | $2.19 | $2.77 | $2.26 | · | $1.45 | |
| EPS (TTM) | $-0.54 | $-2.29 | · | $8.56 | $6.97 | $6.51 | · | $-5.95 | $-6.32 | $-7.69 | · | $-8.65 | $-8.42 | $-7.89 | · | $-7.47 |
Valorisation (TTM)
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.01B | $827M | · | $1.78B | $1.76B | $1.77B | · | $901M | $900M | $928M | · | $798M | $819M | $770M | · | $697M | |
| Net Income TTM | $-38M | $-187M | · | $752M | $629M | $595M | · | $-453M | $-480M | $-579M | · | $-642M | $-618M | $-571M | · | $-531M | |
| Market Cap | $6.80B | $5.65B | · | $4.91B | $3.88B | $4.04B | · | $2.85B | $2.35B | $2.23B | · | $1.69B | $3.06B | $3.59B | · | $3.61B | |
| Enterprise Value | $5.16B | $4.04B | · | $3.50B | $2.17B | $2.30B | · | $2.13B | $1.54B | $1.63B | · | $1.97B | $3.30B | $3.87B | · | $3.60B | |
| P/E | -151.1 | -29.8 | · | 7.2 | 7.0 | 7.8 | · | -6.2 | -4.8 | -3.8 | · | -2.6 | -4.8 | -6.1 | · | -6.7 | |
| P/S | 6.7 | 6.8 | · | 2.8 | 2.2 | 2.3 | · | 3.2 | 2.6 | 2.4 | · | 2.1 | 3.7 | 4.7 | · | 5.2 | |
| P/B | -41.1 | -31.3 | · | -31.5 | -18.8 | -21.7 | · | -2.7 | -2.4 | -2.5 | · | -2.5 | -5.3 | -7.8 | · | -15.9 | |
| P / Cash Flow | · | -95.6 | · | · | · | 4.6 | · | · | · | 31.5 | · | · | · | -121.6 | · | · | |
| EV / Revenue | 5.1 | 4.9 | · | 2.0 | 1.2 | 1.3 | · | 2.4 | 1.7 | 1.8 | · | 2.5 | 4.0 | 5.0 | · | 5.2 | |
| Earnings Yield | -0.66% | -3.4% | · | 14.0% | 14.3% | 12.8% | · | -16.0% | -20.7% | -26.4% | · | -38.6% | -20.7% | -16.3% | · | -14.9% |
Période la plus récente à gauche · valeurs nulles affichées comme ·
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenu | $1.73B | $807M | $938M | $699M | $539M |
| Marge d'exploitation % | 50.1% | -37.5% | -46.9% | · | -69.5% |
| Résultat net | $683M | $-363M | $-627M | $-559M | $-524M |
| BPA dilué | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dette / Capitaux propres | -1.4 | -0.3 | -0.3 | · | 300.0 |
| Ratio de liquidité | 2.3 | 2.4 | 2.0 | · | 1.9 |
| Ratio de liquidité réduite | 2.2 | 2.2 | 1.7 | · | 1.7 |
| Métrique | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $702M | $-114M | $-187M | · | $-280M |
Détenteurs institutionnels (13F) 403 déclarants · $8.6B total · Au 30 septembre 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
Détenteurs
403
Valeur détenue
$8.6B
Nouvelles positions
76
Positions clôturées
43
Activité institutionnelle — Q2 2026 vs trimestre précédent
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 76 (+7 vs T. préc.) | 43 (-7 vs T. préc.) | 140 (+3 vs T. préc.) | 114 (+10 vs T. préc.) | -1.4M |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| BlackRock, Inc. | $1 139 088 671 | 13 964 554 | 13,21% | Actions |
| VANGUARD GROUP INC | $668 691 300 | 8 803 203 | 7,75% | Actions |
| RTW INVESTMENTS, LP | $631 875 072 | 7 746 415 | 7,33% | Actions |
| JANUS HENDERSON GROUP PLC | $489 997 100 | 7 193 433 | 5,68% | Actions |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $401 986 014 | 4 928 111 | 4,66% | Actions |
| STATE STREET CORP | $375 136 515 | 4 598 952 | 4,35% | Actions |
| WELLINGTON MANAGEMENT GROUP LLP | $336 743 228 | 4 128 273 | 3,90% | Actions |
| VANGUARD CAPITAL MANAGEMENT LLC | $305 000 589 | 3 739 127 | 3,54% | Actions |
| GEODE CAPITAL MANAGEMENT, LLC | $180 089 116 | 2 207 376 | 2,09% | Actions |
| TORONTO DOMINION BANK | $176 668 031 | 2 165 846 | 2,05% | Actions |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $159 563 645 | 1 956 156 | 1,85% | Actions |
| Hood River Capital Management LLC | $141 818 662 | 1 738 613 | 1,64% | Actions |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $140 519 660 | 1 722 688 | 1,63% | Actions |
| D. E. Shaw & Co., Inc. | $126 345 323 | 1 548 919 | 1,47% | Actions |
| TANG CAPITAL MANAGEMENT LLC | $122 355 000 | 1 500 000 | 1,42% | Actions |
| BANK OF AMERICA CORP /DE/ | $118 462 234 | 1 452 277 | 1,37% | Actions |
| Driehaus Capital Management LLC | $117 469 528 | 1 440 107 | 1,36% | Actions |
| FMR LLC | $114 056 206 | 1 398 261 | 1,32% | Actions |
| Jefferies Financial Group Inc. | $110 693 916 | 1 357 042 | 1,28% | Actions |
| FULLER & THALER ASSET MANAGEMENT, INC. | $94 361 749 | 1 156 819 | 1,09% | Actions |
| Pictet Asset Management Holding SA | $93 629 635 | 1 147 844 | 1,09% | Actions |
| MORGAN STANLEY | $90 026 886 | 1 103 675 | 1,04% | Actions |
| ARMISTICE CAPITAL, LLC | $87 393 690 | 1 071 395 | 1,01% | Actions |
| Blue Sparrow, LLC /DE | $85 705 599 | 1 050 700 | 0,99% | Actions |
| FRANKLIN RESOURCES INC | $83 799 082 | 1 027 327 | 0,97% | Actions |
| Invesco Ltd. | $76 804 761 | 941 581 | 0,89% | Actions |
| Palo Alto Investors LP | $74 950 268 | 918 846 | 0,87% | Actions |
| NORTHERN TRUST CORP | $71 783 966 | 880 029 | 0,83% | Actions |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $64 449 436 | 790 112 | 0,75% | Actions |
| CITADEL ADVISORS LLC | $60 999 840 | 747 822 | 0,71% | Actions |
| RENAISSANCE TECHNOLOGIES LLC | $59 015 895 | 723 500 | 0,68% | Actions |
| Boston Partners | $58 606 553 | 718 574 | 0,68% | Actions |
| JUPITER ASSET MANAGEMENT LTD | $57 706 697 | 707 450 | 0,67% | Actions |
| MARSHALL WACE, LLP | $57 489 476 | 704 787 | 0,67% | Actions |
| JPMORGAN CHASE & CO | $56 073 502 | 684 042 | 0,65% | Actions |
| ARMISTICE CAPITAL, LLC | $53 836 200 | 660 000 | 0,62% | Option d'achat |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $53 377 940 | 654 382 | 0,62% | Actions |
| DIMENSIONAL FUND ADVISORS LP | $52 017 434 | 637 704 | 0,60% | Actions |
| GOLDMAN SACHS GROUP INC | $50 430 408 | 618 247 | 0,58% | Actions |
| LOOMIS SAYLES & CO L P | $48 156 807 | 590 374 | 0,56% | Actions |
| VANGUARD FIDUCIARY TRUST CO | $47 953 943 | 587 887 | 0,56% | Actions |
| Nuveen, LLC | $47 622 931 | 583 829 | 0,55% | Actions |
| Bank of New York Mellon Corp | $45 145 865 | 553 462 | 0,52% | Actions |
| PRINCIPAL FINANCIAL GROUP INC | $44 181 166 | 541 635 | 0,51% | Actions |
| VOYA INVESTMENT MANAGEMENT LLC | $43 992 251 | 539 319 | 0,51% | Actions |
| Ensign Peak Advisors, Inc | $41 442 128 | 508 056 | 0,48% | Actions |
| AMERICAN CENTURY COMPANIES INC | $40 866 277 | 500 995 | 0,47% | Actions |
| FEDERATED HERMES, INC. | $39 432 896 | 483 424 | 0,46% | Actions |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $36 050 432 | 441 957 | 0,42% | Actions |
| Parkman Healthcare Partners LLC | $35 539 315 | 435 691 | 0,41% | Actions |
Activistes et détenteurs de 5%+ 3 participations
Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.
| Déclarant | Déposé | Participation | Statut | Objectif | Dépôt |
|---|---|---|---|---|---|
| Brookside Capital Partners Fund, L.P., Brookside Capital Trading Fund, L.P. ×5 dépôts | 30 janvier 2015 | · | Dépôt initial | · | SEC |
| HBM Healthcare Investments (Cayman) Ltd. (“HBM”) ×2 dépôts | 12 novembre 2014 | · | Dépôt initial | · | SEC |
| HBM Healthcare Investments (Cayman) Ltd. | 5 juillet 2013 | · | Dépôt initial | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Initiés de la société 37 initiés · 15 dirigeants · 20 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| Matthew B. Klein | CHIEF EXECUTIVE OFFICER | 4 août 2026 S | 383 868 | 0 | 13 | $-4 219 888 |
| Stuart Walter Peltz | CHIEF EXECUTIVE OFFICER | 31 janvier 2023 S | 54 903 | 0 | 0 | $0 |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | 14 juillet 2026 S | 83 986 | 0 | 3 | $-652 864 |
| Emily Luisa Hill | CHIEF FINANCIAL OFFICER | 27 mars 2023 S | 38 925 | 0 | 0 | $0 |
| Shane William Charles Kovacs | Chief Financial Officer | 9 mai 2017 M | 37 850 | 0 | 0 | $0 |
| Claudia De Oliveira Ribeiro Hirawat | President | 15 janvier 2015 M | 39 247 | 0 | 0 | $0 |
| Marcio Souza | Chief Operating Officer | 10 février 2020 M | 6 744 | 0 | 0 | $0 |
| Mark Elliott Boulding | EXEC. VP AND CLO | 17 août 2026 M | 105 272 | 0 | 63 | $-5 955 553 |
| Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | 9 juillet 2026 M | 60 299 | 0 | 62 | $-25 989 291 |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 17 juin 2026 M | 70 199 | 0 | 5 | $-1 941 426 |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 10 juin 2026 S | 73 411 | 0 | 28 | $-7 477 160 |
| Lee Scott Golden | EVP & CHIEF MEDICAL OFFICER | 2 avril 2026 S | 79 115 | 0 | 6 | $-1 081 515 |
| Mark Rothera | Chief Commercial Officer | 24 mai 2017 M | 33 739 | 0 | 0 | $0 |
| Tuyen Ong | Chief Medical Officer | 3 janvier 2017 A | 6 000 | 0 | 0 | $0 |
| Robert J. Spiegel | Chief Medical Officer | 4 janvier 2016 A | 3 239 | 0 | 0 | $0 |
| Glenn Steele JR MD PHD | Administrateur | 30 septembre 2026 M | 22 500 | 0 | 2 | $-1 698 120 |
| Michael Schmertzler | Administrateur | 17 septembre 2026 S | 1 296 594 | 0 | 16 | $-6 313 453 |
| Hege Elisabeth Sollie-Zetlmayer | Administrateur | 28 juillet 2026 A | 52 526 | 0 | 0 | $0 |
| Mary L. Smith | Administrateur | 9 juillet 2026 M | 21 813 | 0 | 2 | $-1 425 060 |
| Jessica Caroline Chutter | Administrateur | 24 mars 2026 A | 7 333 | 0 | 0 | $0 |
| Stephanie Okey | Administrateur | 10 mars 2026 M | 8 000 | 0 | 3 | $-1 463 076 |
| Emma Reeve | Administrateur | 5 janvier 2026 M | 10 666 | 0 | 15 | $-4 229 530 |
| Alethia Young | Administrateur | 2 janvier 2026 A | 21 067 | 0 | 0 | $0 |
| Allan Steven Jacobson | Administrateur | 2 janvier 2026 A | 21 451 | 0 | 11 | $-2 912 018 |
| Jerome B Zeldis | Administrateur | 2 janvier 2026 A | 22 500 | 0 | 0 | $0 |
| William F. Bell Jr. | Administrateur | 15 février 2024 A | 10 333 | 0 | 0 | $0 |
| Dawn Svoronos | Administrateur | 9 juin 2022 S | 29 017 | 0 | 0 | $0 |
| Cameron Geoffrey Mcdonough | Administrateur | 3 janvier 2017 A | · | 0 | 0 | $0 |
| Adam Koppel | Administrateur | 3 janvier 2017 A | 2 333 333 | 0 | 0 | $0 |
| Ronald C Renaud JR | Administrateur | 3 janvier 2017 A | · | 0 | 0 | $0 |
| Richard Aldrich | Administrateur | 8 juin 2015 M | 0 | 0 | 0 | $0 |
| Michael L Kranda | Administrateur | 16 mars 2015 S | 2 242 | 0 | 0 | $0 |
| Axel Bolte | Administrateur | 25 juin 2013 P | 20 000 | 0 | 0 | $0 |
| HBM Healthcare Investments (Cayman) Ltd. | Détenteur de 10% | 17 décembre 2013 S | 2 441 504 | 0 | 0 | $0 |
| David P Southwell | · | 2 janvier 2026 A | 20 850 | 0 | 0 | $0 |
| Complete Pharma Holdings II, LLC | · | 28 avril 2017 J | 0 | 0 | 0 | $0 |
| CREDIT SUISSE/ | · | 25 juin 2013 C | 2 256 882 | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Détention d'ETF Détenu par 68 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
| Fonds | Poids | Unités | Au | Source |
|---|---|---|---|---|
| IBRN · iShares Trust | 3,74% | 4 145 SH | 11 septembre 2026 | Quotidien |
| PSCH · Invesco Exchange-Traded Fund Trust … | 2,93% | 79 357 SH | 2 octobre 2026 | Quotidien |
| PBE · Invesco Exchange-Traded Fund Trust | 2,47% | 159 717 SH | 2 octobre 2026 | Quotidien |
| MEDI · Harbor ETF Trust | 1,31% | 7 913 NS | 31 juillet 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,25% | 18 062 NS | 31 juillet 2026 | N-PORT |
| RZG · Invesco Exchange-Traded Fund Trust | 1,23% | 22 852 SH | 2 octobre 2026 | Quotidien |
| JSML · Janus Detroit Street Trust | 1,03% | 54 825 NS | 31 juillet 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 0,94% | 145 033 NS | 31 juillet 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,74% | 98 733 SH | 19 août 2026 | Quotidien |
| VAMO · Cambria ETF Trust | 0,72% | 11 494 NS | 31 juillet 2026 | N-PORT |
| VMAX · Lattice Strategies Trust | 0,71% | 5 120 NS | 31 juillet 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,63% | 46 006 NS | 31 juillet 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,49% | 658 NS | 31 juillet 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,42% | 3 031 NS | 31 juillet 2026 | N-PORT |
| IBB · iShares Trust | 0,40% | 613 266 SH | 11 septembre 2026 | Quotidien |
| BRNY · EA Series Trust | 0,39% | 33 006 NS | 31 juillet 2026 | N-PORT |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,37% | 290 018 SH | 19 août 2026 | Quotidien |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,36% | 5 891 SH | 2 octobre 2026 | Quotidien |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,34% | 75 795 SH | 19 août 2026 | Quotidien |
| ESSC · Strategy Shares | 0,34% | 1 785 NS | 31 juillet 2026 | N-PORT |
| IWO · iShares Trust | 0,31% | 664 357 SH | 11 septembre 2026 | Quotidien |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,27% | 22 505 NS | 31 juillet 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0,25% | 25 676 NS | 31 juillet 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,24% | 3 125 NS | 31 juillet 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,20% | 477 030 SH | 19 août 2026 | Quotidien |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,19% | 19 797 NS | 31 juillet 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,19% | 3 667 NS | 31 juillet 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,19% | 1 099 640 SH | 19 août 2026 | Quotidien |
| IWM · iShares Trust | 0,18% | 2 118 779 SH | 11 septembre 2026 | Quotidien |
| RSSL · Global X Funds | 0,18% | 39 691 NS | 31 juillet 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,18% | 629 NS | 31 juillet 2026 | N-PORT |
| ISCG · iShares Trust | 0,16% | 23 005 SH | 11 septembre 2026 | Quotidien |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,16% | 65 468 SH | 2 octobre 2026 | Quotidien |
| LRGF · iShares Trust | 0,16% | 84 774 SH | 11 septembre 2026 | Quotidien |
| VFMO · VANGUARD WELLINGTON FUND | 0,14% | 35 428 SH | 19 août 2026 | Quotidien |
| FSMD · FIDELITY COVINGTON TRUST | 0,14% | 51 459 NS | 31 juillet 2026 | N-PORT |
| FHEQ · Fidelity Greenwood Street Trust | 0,14% | 18 636 NS | 31 juillet 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,13% | 5 320 SH | 2 octobre 2026 | Quotidien |
| FBUF · Fidelity Greenwood Street Trust | 0,12% | 413 NS | 31 juillet 2026 | N-PORT |
| FYEE · Fidelity Greenwood Street Trust | 0,11% | 3 600 NS | 31 juillet 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,10% | 224 327 NS | 31 juillet 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,08% | 952 071 SH | 19 août 2026 | Quotidien |
| VB · VANGUARD INDEX FUNDS | 0,08% | 1 902 509 SH | 19 août 2026 | Quotidien |
| VHT · VANGUARD WORLD FUND | 0,08% | 211 842 SH | 19 août 2026 | Quotidien |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,08% | 6 756 NS | 31 juillet 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,07% | 33 487 NS | 31 juillet 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,06% | 12 627 NS | 31 juillet 2026 | N-PORT |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,06% | 18 932 SH | 2 octobre 2026 | Quotidien |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,06% | 10 557 SH | 19 août 2026 | Quotidien |
| ESML · iShares Trust | 0,06% | 22 893 SH | 11 septembre 2026 | Quotidien |
| WSML · iShares Trust | 0,04% | 4 360 SH | 11 septembre 2026 | Quotidien |
| TILT · FlexShares Trust | 0,01% | 4 108 NS | 31 juillet 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,01% | 2 636 335 SH | 19 août 2026 | Quotidien |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 66 405 SH | 19 août 2026 | Quotidien |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 6 819 SH | 19 août 2026 | Quotidien |
| ESGV · VANGUARD WORLD FUND | 0,01% | 18 275 SH | 19 août 2026 | Quotidien |
| ITOT · iShares Trust | 0,01% | 109 219 SH | 11 septembre 2026 | Quotidien |
| IWV · iShares Trust | 0,01% | 22 686 SH | 10 septembre 2026 | Quotidien |
| DFAC · Dimensional ETF Trust | 0,01% | 43 296 NS | 31 juillet 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 1 090 NS | 31 juillet 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 284 NS | 31 juillet 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 249 NS | 31 juillet 2026 | N-PORT |
| IJR · iShares Trust | · | 5 061 986 SH | 10 septembre 2026 | Quotidien |
| IJT · iShares Trust | · | 784 746 SH | 9 septembre 2026 | Quotidien |
| IWN · iShares Trust | · | 114 658 SH | 11 septembre 2026 | Quotidien |
| XJR · iShares Trust | · | 11 464 SH | 31 août 2026 | Quotidien |
| ISCB · iShares Trust | · | 3 281 SH | 11 septembre 2026 | Quotidien |
| SMLF · iShares Trust | · | 64 380 SH | 11 septembre 2026 | Quotidien |
PTCT Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
notation · 21 analystes
ACHAT
Objectif médian
$101.00
+59,2%
6 28,6%
Achat fort
11 52,4%
Achat
3 14,3%
Conserver
1 4,8%
Vente
0 0,0%
Vente forte
Objectif de cours à 12 mois
14 analystes · 2026-10-01Objectif moyen $101.79 +60,4%
← En dessous de tous les objectifs
Prix actuel $63.46
Bas$70.00
Moyenne$101.79
Haut$137.00
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
Base F.A., prix à la clôture de la dernière fin d'exercice de chaque société.
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| PTCT | $6.19B | 9.8 | 114.5% | 39.4% | -331.5% | · |
| SRRK | $4.78B | -13.4 | · | · | -157.9% | · |
| ORKA | $1.48B | -3.3 | · | · | -25.9% | · |
| COGT | $5.72B | -16.4 | · | · | -83.1% | · |
| MIRM | $4.10B | -168.1 | 54.7% | -4.5% | -8.2% | · |
| TVTX | $3.47B | -131.8 | 110.5% | -5.2% | -34.6% | · |
| ERAS | $1.06B | -8.5 | · | · | -35.7% | · |
| DNTH | $1.78B | -9.8 | -67.3% | -7973.3% | -40.8% | · |
| RLAY | $1.47B | -5.3 | 53.4% | -1800.6% | -44.9% | · |
Signaux de trading Signaux d'achat/vente récents avec prix d'entrée et ratio risque/récompense
Aucun signal ouvert pour le moment — aucune carte n'est remplie, et c'est honnête.
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
Choisissez les indicateurs qui vous importent — cliquez sur le + à côté de n'importe quelle ligne dans les Fondamentaux complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.
Source : Dépôt SEC 10-Q le Jul 30, 2026